Denali Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell DNLI and other ETFs, options, and stocks.About DNLI
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau.
CEORyan J. Watts
CEORyan J. Watts
Employees422
Employees422
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded2013
Founded2013
Employees422
Employees422
DNLI Key Statistics
Market cap2.44B
Market cap2.44B
Price-Earnings ratio-5.95
Price-Earnings ratio-5.95
Dividend yield—
Dividend yield—
Average volume1.68M
Average volume1.68M
High today$17.39
High today$17.39
Low today$16.20
Low today$16.20
Open price$16.48
Open price$16.48
Volume2.57M
Volume2.57M
52 Week high$33.33
52 Week high$33.33
52 Week low$10.57
52 Week low$10.57
DNLI News
TipRanks 3d
Denali Therapeutics Faces FDA Review ExtensionElevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 3d
Denali Therapeutics announces FDA extension of tividenofusp BLA review timelineDenali Therapeutics (DNLI) announced that the FDA has extended its review timeline of the biologics license application seeking accelerated approval of tivideno...
Analyst ratings
100%
of 18 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own DNLI. This list is generated using Robinhood data, and it’s not a recommendation.